Trnavská Z, Trnavský K
Naunyn Schmiedebergs Arch Pharmacol. 1984 Aug;327(1):81-5. doi: 10.1007/BF00504996.
The binding of non-steroidal antirheumatic drug piroxicam to human serum albumin, human plasma and serum has been studied by equilibrium dialysis at 22 degrees C, pH 7.4. The binding data were analyzed according to Scatchard model. The values of binding parameters obtained for human serum albumin are quite similar to those obtained for human plasma and serum (N1 = 0.3, K1 = 3.0 x 10(5) l/mol; N2 = 7, K2 = 3.5 x 10(3) l/mol). We suggest that piroxicam interacts with the albumin fraction in human plasma proteins. The displacement of piroxicam (in the therapeutical concentration of 4.5 x 10(5) mol/l) from the binding to human serum albumin and human plasma has been studied. The concentration of albumin and albumin fraction in plasma was 2.9 x 10(-4) mol/l. The displacement substances were drugs--diazepam, warfarin and salicylic acid, and endogenous substances-bilirubin and palmitic acid. Only in the presence of salicylic acid in high clinical concentration (14.5 x 10(-4) mol/l) and palmitic acid in the molar ratio to albumin 5:1, free piroxicam substantially increased, which may be of clinical significance. Other studied substances displaced piroxicam only in high concentrations exceeding the therapeutical and physiological range. The evidence was found for the similarity of piroxicam and warfarin high-affinity binding site.
在22℃、pH 7.4条件下,采用平衡透析法研究了非甾体类抗风湿药吡罗昔康与人血清白蛋白、人血浆及血清的结合情况。根据Scatchard模型对结合数据进行分析。获得的人血清白蛋白结合参数值与人血浆及血清的非常相似(N1 = 0.3,K1 = 3.0×10⁵ l/mol;N2 = 7,K2 = 3.5×10³ l/mol)。我们认为吡罗昔康与人血浆蛋白中的白蛋白部分相互作用。研究了吡罗昔康(治疗浓度为4.5×10⁻⁵ mol/l)从与人血清白蛋白及人血浆的结合中的置换情况。血浆中白蛋白及白蛋白部分的浓度为2.9×10⁻⁴ mol/l。置换物质为药物——地西泮、华法林和水杨酸,以及内源性物质——胆红素和棕榈酸。仅在临床高浓度水杨酸(14.5×10⁻⁴ mol/l)及棕榈酸与白蛋白的摩尔比为5:1存在时,游离吡罗昔康大幅增加,这可能具有临床意义。其他研究物质仅在超过治疗和生理范围的高浓度下才能置换吡罗昔康。发现了吡罗昔康与华法林高亲和力结合位点相似的证据。